Sonia Kamboj, MD
Allergy & Immunology · Marrero, LANPI 1972706661
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (44.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Incyte Corporation at 28.1% of the total. Reporting peaked in 2024 at $9,627 and has fallen 56.2% since, to $4,219 in 2025. Among allergy & immunology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 407 payments — averaging $71.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$8K
- Genentech, Inc.$5K
- Sanofi$4K
- GSK$3K
- Teva Pharmaceuticals USA, Inc.$2K
- AstraZeneca$2K
- plus $5K from 27 others
What the payments were for
- Consulting fees$12,06142%
- Speaking & faculty fees$1,6806%
- Travel & lodging$2,0297%
- Food & beverage$12,89945%
- Education$3001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 28 | $8,154 |
| Genentech, Inc. | 5 | $5,056 |
| Sanofi | 42 | $4,403 |
| GSK | 104 | $2,986 |
| Teva Pharmaceuticals USA, Inc. | 7 | $1,800 |
| AstraZeneca | 63 | $1,685 |
| Regeneron Healthcare Solutions, Inc. | 54 | $1,424 |
| Novartis | 22 | $947 |
| Pfizer | 8 | $339 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $324 |
| Optinose US, Inc. | 5 | $243 |
| Genentech USA, Inc. | 8 | $230 |
| Sanofi-aventis U.S. LLC | 2 | $200 |
| Organon | 3 | $166 |
| Shire North American Group Inc | 8 | $159 |
| Amgen | 6 | $154 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $144 |
| Boehringer Ingelheim | 6 | $89 |
| Blueprint Medicines Corporation | 1 | $55 |
| LEO Pharma Inc. | 2 | $54 |
| Kaleo, Inc. | 3 | $53 |
| AbbVie | 2 | $43 |
| Aimmune Therapeutics, Inc. | 2 | $42 |
| Alk-abello, Inc | 2 | $35 |
| CSL Behring | 1 | $31 |
| Verona Pharma, Inc. | 1 | $26 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Inspire Medical Systems, Inc. | 1 | $20 |
| Phadia US Inc. | 1 | $20 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $19 |
| Merck | 1 | $13 |
| Cycle Pharmaceuticals Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPZELURA$7,565
- XOLAIR$4,972
- ProAir Digihaler$1,680
- AirDuo RespiClick$1,680
- ArmonAir Digihaler$1,680
- DUPIXENT$1,005
- NUCALA$924
- TEZSPIRE$259
- TRELEGY ELLIPTA$227
- VTAMA$133
- FASENRA$125
- EUCRISA$115
- AIRSUPRA$108
How this compares
$28,969 in reported general payments places this provider in the 90th percentile of 62 allergy & immunology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 38 | $148,372 |
| TezspireTezepelumab-Ekko | 24 | $101,856 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $47,277 |
| Breo ElliptaFluticasone/Vilanterol | 45 | $18,995 |
| SymbicortBudesonide/Formoterol Fumarate | 31 | $9,322 |
| Levocetirizine Dihydrochloride | 229 | $3,667 |
| Epinephrine | 16 | $2,861 |
| Azelastine Hcl | 82 | $2,468 |
| Montelukast Sodium | 191 | $2,052 |
| Fluticasone Propionate | 146 | $1,846 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 61 | $1,228 |
| Ipratropium Bromide | 29 | $651 |
| Hydroxyzine Hcl | 51 | $498 |
| Azithromycin | 17 | $214 |
| Hydrocortisone | 20 | $187 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech, Inc.Xolair | $5,056 | $148,37238 claims |
| AstraZenecaTezspire, Symbicort | $1,685 | $111,17855 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $2,986 | $66,27288 claims |
| Hikma Pharmaceuticals USAEpinephrine | $21 | $2,86116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 62 allergy & immunology providers in Louisiana.
Other allergy & immunology in Marrero
- David KaufmanShreveport$678K
- Reena MehtaNew Orleans$159K
- Kenneth ParisNew Orleans$150K
- Brice RolstonCovington$54K
- Caroline CapertonShreveport$52K
- Erin PrattLafayette$17K
- Adrianne EdmundsonPrairieville$12K
- Cheryl WilliamsNew Orleans$12K
- Sarah QayumMetairie$11K
- David SchneiderMetairie$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.